CLAIMS

1. Use of an oncolytic virus selected from the group consisting of Delta-24 and Delta-24 RGD in the manufacture of a medicament for treating cancer in a patient having a primary or metastatic brain tumor and being treated with a Th1 stimulating agent, wherein said Th1 stimulating agent is a PD-1/PD-L1 receptor antagonist.

2. Use of a Th1 stimulating agent in the manufacture of a medicament for treating cancer in a patient having a primary or metastatic brain tumor and being treated with an oncolytic virus selected from the group consisting of Delta-24 and Delta-24 RGD, wherein said Th1 stimulating agent is a PD-1/PD-L1 receptor antagonist.

3. The use of claims 1-2, wherein said PD-1/PD-L1 receptor antagonist is selected from the group consisting of MDX-1106, MK-3475, AMP-224, Pidilizumab, and MDX-1105.

4. The use of claims 1-3, wherein the virus is to be administered intratumorally.

5. The use of claim 4, wherein the virus is to be administered intratumorally by injection into multiple tumor sites.

6. The use of claims 1-3, wherein the virus is to be administered intravascularly, such as intravenously or intraarterially.

7. The use according to any one of the preceding claims, wherein said brain tumor is a glioma.

8. The use of claim 7, wherein the glioma is low-grade glioma.

9. The use of claim 7, wherein the glioma is high-grade glioma.

10. The use of claims 1-9, wherein the oncolytic virus is to be administered to the patient prior to the Th1 stimulating agent.

11. The use of claims 1-9, wherein the oncolytic virus is to be administered to the patient after the Th1 stimulating agent.

12. The use according to any one of claims 1-6, 10 and 11, where the brain tumor is primary brain tumor.

13. The use according to any one of claims 1-6, 10 and 11, where the brain tumor is metastatic brain tumor.